No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma

Published Date: 16 Sep 2024

Data support that ICI rechallenge should be discouraged in patients with advanced RCC

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The use of biomarkers in the treatment of breast lumps is at a crossroads.

2.

According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.

3.

How Do Younger People Fare With Stool Tests for CRC Screening?

4.

Dual Targeted CAR-T Yields 99% Response Rate in Pediatric ALL

5.

Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot